Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
about
Oral Delivery of Protein Drugs Bioencapsulated in Plant CellsGlobal Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate).Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa.Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.Application of current knowledge to the management of bleeding events during immune tolerance induction.An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.Haemophilia therapies.Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.International workshop on immune tolerance induction: consensus recommendations.Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors.Key issues in inhibitor management in patients with haemophilia.Novel drugs to treat hemophilia.How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.Factor VIII therapy for hemophilia A: current and future issues.When is enough…enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors.Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors.Prevention of bleeding in hemophilia patients with high-titer inhibitors.Animal models of FVIIa gene expression: their role in the future development of haemophilia treatmentLow incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.Inhibitor challenges in the paediatric setting.A retrospective postlicensure survey of FEIBA efficacy and safety.Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.Healthcare resource utilization among haemophilia A patients in the United States.First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII.Women leaders in hematology: Inspirations & insights.Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.Emicizumab should be prescribed independent of immune tolerance induction
P2860
Q28079063-755EA6EF-98DE-48F4-AB9D-91D8921DFC07Q31041664-3F06F462-EFC0-44FC-85F5-01F99978B9AFQ34999749-FF56F34E-3002-4DA5-80B3-C65C4D01A4C7Q35248264-00B78CF0-B7ED-4F8B-AE72-B6BEE8C02167Q36643874-03C9BBFE-AAF6-4310-94A6-5C4859757AC0Q36661836-50A2ECF9-E29B-4E91-BE18-8CE2BD9709D6Q36810282-DB187CFE-A84B-414A-AAAB-1E30ED6C0399Q36828144-86F7830B-016A-45A9-B49E-183280CE8481Q36861097-B6E2710D-ABD5-4C8B-A75E-D7B82388C5E3Q36981731-6CF387D7-A4B7-4024-9187-0AAAB9868243Q36985329-D731CA0A-FA63-4E1F-B49E-38777C9DDED9Q37602415-578135CE-0CAD-4138-AC03-A3723A4BF17EQ37775029-9832411C-E4E2-49A8-9FA3-325B458EB48AQ38060224-2BFA77CD-225C-4E36-9AE9-CBCF8DF7AEDAQ38203350-91077F9A-0CBF-4083-81A0-736A27DB49A1Q38221821-86A20818-D97B-4811-8CD7-F7B704E79017Q38325328-3CADBA7E-255F-4AEC-8F47-5FB2BDE0226EQ38456352-70EDB8AE-CD5E-4A6A-8EB2-83661BD4EEE4Q39898071-A9CABC85-EBC6-41B9-B90A-4A510A8B90E9Q44746723-ABFD7FDC-2C78-498C-88D9-28177EA09E20Q44988735-E230DCC9-C303-4696-BC3E-424ECF10A50DQ45855143-5AF071C7-999E-43CD-9A75-9D2470EF171EQ45859618-523EF6CE-2883-4D50-829D-D331C6F7F635Q45868039-1EE46949-3B94-49F8-85D4-E2171F704450Q45868043-A81EEE05-F8F5-4556-A3BC-8454E9DC48FBQ45872212-58135AB7-417E-4FA3-BCF1-46E10A4C7C69Q45874612-4B095E98-CE33-4212-B8A1-C6A44FBA9E50Q45877949-2C7A0544-B40E-4246-9701-0F2D4A0DCA83Q45878007-30264D75-25CC-4766-87A5-B80EF1E48FD5Q45882018-D5C9A659-4C34-4EE0-B096-47D3D1783FCAQ45883000-A2B93891-B02C-4325-A2C7-7F12C5DB151EQ45887994-E1B08E7F-2ECC-4635-8A3D-9648C8D5D827Q57795846-D153B233-92D9-4CEE-8F34-DFE436F9CB93
P2860
Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Prevention of bleeds in hemoph ...... g data and clinical direction.
@ast
Prevention of bleeds in hemoph ...... g data and clinical direction.
@en
type
label
Prevention of bleeds in hemoph ...... g data and clinical direction.
@ast
Prevention of bleeds in hemoph ...... g data and clinical direction.
@en
prefLabel
Prevention of bleeds in hemoph ...... g data and clinical direction.
@ast
Prevention of bleeds in hemoph ...... g data and clinical direction.
@en
P356
P1476
Prevention of bleeds in hemoph ...... g data and clinical direction.
@en
P2093
Cindy A Leissinger
P304
P356
10.1002/AJH.20162
P577
2004-10-01T00:00:00Z